MDM2 and neoplasm: In conclusion, MDM2 inhibitors in combination with ICI therapy can improve anti-tumor effects and tumor-overcoming resistance when MDM2 monotherapy is not ideal, and combination therapy does not appear to increase MDM2 inhibitor toxicity; however, further clinical trials are needed to validate these findings.